Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas

This article was originally published in The Pink Sheet Daily

Executive Summary

The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.


Related Content

Biopharma Dealmaking Quarterly Statistics, Q3 2013
Deals Of The Week: Wondering Where Have The Private Biotech Take-Outs Gone?
AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub
Deals Of The Week: Busy ROR Gamma T Space Offers Small Molecule Promise In Autoimmune Disorders
AstraZeneca’s Plan To Spur Brilinta Sales Is On Track, CEO Says
P&G Spinout Spins Off Another Company, While Looking To Partner Mid-Stage Oral Anemia Candidate
Bringing New Blood to the Anemia Market
FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
Death Reported In Phase II Trial For Astellas/FibroGen’s Oral EPO Candidate


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts